各大新药开发团队,无论是三四个人的小team,还是制药巨头的研发部门,都在这里报告自己的临床研究进展。然后,临床数据一出,资本市场就上演此起彼伏的上涨...查看全文
chuminhua2019-12-11 15:44
12/10,Forty Seven公司$Forty Seven(FTSV)$ 在第61届美国血液学会(ASH)年会上宣布,其靶向CD47的单克隆抗体magrolimab,与azacitidine组成的联合疗法,在治疗骨髓增生异常综合症(MDS)和急性髓系白血病(AML)患者的1b期试验中,表现出优于azacitidine单药疗法的治疗效果。在AML患者亚组中,患...查看全文
啃医药股的熊猫2019-05-15 12:00
$Forty Seven(FTSV)$ Forty Seven与$阿斯利康(AZN)$ 阿斯利康合作,共同研究NHL新三联疗法。该疗法将CD47抗体5F9与Calquence和利妥昔单抗联用,为患者提供更多治疗方案。 查看全文网页链接查看全文
用户48783635432019-05-15 11:42
【汇众医疗】$阿斯利康(AZN)$ $Forty Seven(FTSV)$ Forty Seven与阿斯利康合作,共同研究NHL新三联疗法。该疗法将Forty Seven研发的CD47抗体5F9与阿斯利康研发的Calquence和利妥昔单抗联用,不含化疗药物。 查看全文网页链接查看全文
$Forty Seven(FTSV)$ 15-12B Securities registration termination [Section 12(b)] Accession Number: 0001104659-20-047951 Act: 34 Size: 20 KB 网页链接
$Forty Seven(FTSV)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000902219-20-000371 Act: 34 Size: 33 KB 网页链接
$Forty Seven(FTSV)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-20-000690 Act: 33 Size: 1 KB 网页链接
$Forty Seven(FTSV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-023727 Size: 19 KB 网页链接
$Forty Seven(FTSV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-023722 Size: 9 KB 网页链接
$Forty Seven(FTSV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-023723 Size: 16 KB 网页链接
$Forty Seven(FTSV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-023724 Size: 14 KB 网页链接
$Forty Seven(FTSV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-023717 Size: 9 KB 网页链接
$Forty Seven(FTSV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-023720 Size: 9 KB 网页链接
$Forty Seven(FTSV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-023714 Size: 19 KB 网页链接